Pancreatic Ductal Adenocarcinoma (PDAC)

Oncology
3
Pipeline Programs
4
Companies
10
Clinical Trials
8 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
CEND-1Phase 21 trial
Active Trials
NCT06261359RecruitingEst. Oct 2026
Bristol Myers Squibb
1 program
1
PumitamigPhase 25 trials
Active Trials
NCT07361497Not Yet Recruiting850Est. Dec 2033
NCT07291076Recruiting129Est. Oct 2031
NCT07297212Recruiting75Est. Jul 2029
+2 more trials
Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
1 program
1
Fostamatinib in combination with chemotherapyPhase 11 trial
Active Trials
NCT06639724RecruitingEst. Dec 2028
ExThera Medical
ExThera MedicalCA - Martinez
1 program
ONCObindN/A1 trial
Active Trials
NCT06481397Completed5Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
2031
Bristol Myers SquibbPumitamig
Bristol Myers SquibbPumitamig
Bristol Myers SquibbPumitamig
Bristol Myers SquibbPumitamig
Bristol Myers SquibbPumitamig
Bristol Myers SquibbPumitamig
Qilu PharmaceuticalCEND-1
Bristol Myers SquibbPumitamig
Rigel PharmaceuticalsFostamatinib in combination with chemotherapy
ExThera MedicalONCObind

Clinical Trials (10)

Total enrollment: 3,603 patients across 10 trials

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Start: Apr 2026Est. completion: Dec 2033850 patients
Phase 3Not Yet Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Start: Oct 2025Est. completion: Sep 2030558 patients
Phase 3Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Start: Feb 2025Est. completion: Mar 2029621 patients
Phase 3Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Start: Jan 2025Est. completion: Mar 20301,260 patients
Phase 2/3Recruiting

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Start: Jan 2026Est. completion: Jul 202975 patients
Phase 2Recruiting

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Start: Dec 2025Est. completion: Aug 2028105 patients
Phase 2Recruiting

A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma

Start: Mar 2024Est. completion: Oct 2026
Phase 2Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Start: Mar 2026Est. completion: Oct 2031129 patients
Phase 1/2Recruiting
NCT06639724Rigel PharmaceuticalsFostamatinib in combination with chemotherapy

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Start: Dec 2024Est. completion: Dec 2028
Phase 1Recruiting

OSCAR I STUDY - The ONCObind CTC Removal Study

Start: Aug 2024Est. completion: Oct 20245 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

8 actively recruiting trials targeting 3,603 patients
4 companies competing in this space